Education
About Us
Working with TipRanks
Follow Us
ValiRx plc (GB:VAL)
:VAL
VAL Stock Chart & Stats
Day’s Range― - ―
52-Week Range0.38p - 2.80p
Previous CloseN/A
Volume1.58M
Average Volume (3M)3.94M
Market Cap
£2.25M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta-0.12
Next Earnings
Sep 15, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding374,348,660
10 Day Avg. Volume1,589,619
30 Day Avg. Volume3,939,509
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
ValiRx plc News
VAL FAQ
What was ValiRx plc’s price range in the past 12 months?
ValiRx plc lowest share price was 0.38p and its highest was 2.80p in the past 12 months.
What is ValiRx plc’s market cap?
ValiRx plc’s market cap is £2.25M.
When is ValiRx plc’s upcoming earnings report date?
ValiRx plc’s upcoming earnings report date is Sep 15, 2025 which is in 44 days.
How were ValiRx plc’s earnings last quarter?
Currently, no data Available
Is ValiRx plc overvalued?
According to Wall Street analysts ValiRx plc’s price is currently Overvalued.
Does ValiRx plc pay dividends?
ValiRx plc does not currently pay dividends.
What is ValiRx plc’s EPS estimate?
ValiRx plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ValiRx plc have?
ValiRx plc has 374,348,660 shares outstanding.
What happened to ValiRx plc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of ValiRx plc?
Currently, no hedge funds are holding shares in GB:VAL
Company Description
ValiRx plc
ValiRx plc (VAL) is a life sciences company focused on developing innovative treatments for cancer and other serious diseases. Operating primarily in the biotechnology sector, ValiRx is engaged in the research and development of therapeutic solutions aimed at improving patient outcomes. The company leverages its proprietary technologies to advance a pipeline of clinical and pre-clinical drug candidates, targeting various cancer types and other unmet medical needs.
ValiRx plc (VAL) Earnings & Revenues
Currently, no data available
Please return soon. This page is being updated.
Technical Analysis
Ownership Overview
7.41% Insiders
―
Mutual Funds
― Other Institutional Investors
92.59% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---